Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Common Equity for 11 consecutive years, with $122.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 548.68% year-over-year to $122.9 million; the TTM figure through Mar 2026 stood at $122.9 million (up 548.68% YoY), while the FY2025 annual figure was $139.1 million, up 540.02% from the prior year.
• Common Equity declined to $122.9 million in Q1 2026 per RYTM's latest filing, from $139.1 million in the prior quarter.
• Across five years, Common Equity topped out at $281.2 million in Q3 2022 and bottomed at -$11.9 million in Q2 2025.
• Historically, Common Equity has averaged $135.2 million across 5 years, with a median of $148.8 million in 2025.
• On a YoY basis, Common Equity climbed as much as 1226.95% in 2025 and fell as far as 130.27% in 2025.
• Rhythm Pharmaceuticals' Common Equity stood at $264.3 million in 2022, then plunged by 35.76% to $169.8 million in 2023, then sank by 87.2% to $21.7 million in 2024, then surged by 540.02% to $139.1 million in 2025, then slipped by 11.62% to $122.9 million in 2026.
• Business Quant data shows RYTM's Common Equity at $122.9 million in Q1 2026, $139.1 million in Q4 2025, and $148.8 million in Q3 2025.